Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-NK cells (APEL-expanded)
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR-NK cells (APEL-expanded) are an investigational chimeric antigen receptor (CAR) engineered natural killer (NK) cell therapy manufactured using a specialized Albumin Polyvinylalcohol Essential Lipids (APEL) defined medium. This expansion process induces early metabolic reprogramming, resulting in a "stem-like" phenotype (CAR-NK stem) characterized by enlarged, highly active mitochondria and increased spare respiratory capacity (SRC). These modifications enhance metabolic fitness and flexibility, allowing the cells to resist terminal differentiation and exhaustion within the immunosuppressive tumor microenvironment. Developed primarily by researchers at MD Anderson Cancer Center, this platform aims to improve the persistence and serial killing capacity of off-the-shelf NK cell therapies against both hematologic malignancies and solid tumors.
- Other names
- APEL-expanded CAR-NK cellsstem-like CAR-NK cells
02
Targets
Beyond the preview
Go deeper on CAR-NK cells (APEL-expanded).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-NK cells (APEL-expanded).